Condition: Autism · Sponsor: Curemark
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age between 3 and 8 years, inclusive, at the time of signing informed consent/assent in Sponsor 00103 Study * Completion of the Sponsor's 00103 Study who continue to meet eligibility requirements * Currently in the 00102 open label study and continue to meet eligibility requirements * Subjects who initially qualified for 00103 screening, who subsequently failed Baseline entrance criteria for randomization (@Visit 1) Baseline assessment of the ABC eligibility requirement who continue to meet eligibility requirements * Up to 20 subjects 9-17 years of age who directly enroll into this study, who meet the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for Autistic Disorder (AD), screened by the SCQ and confirmed by the ADI-R Exclusion Criteria: * Patient weighing \< 13kg * Allergy to porcine products * Previous sensitization or allergy to trypsin, pancreatin, or pancrelipase * History of severe head trauma, as defined by loss of consciousness or hospitalization, skull fracture or stroke. * Seizure within the last year prior to enrollment, or the need for seizure medications either at present or in the past. * Evidence or history of severe, moderate or uncontrolled systemic disease * Ongoing dietary restriction for allergy or other reasons except nut allergies. Lactose free is allowable but not dairy free. * Inability to ingest the study drug / non-compliance with dosing schedule. * Inability to follow the prescribed dosing schedule. * Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 5 days prior to the initial randomized study period. * Subjects taking an selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days prior to entering the study. * History of premature birth \<35 weeks gestation. * Prior history of stroke in utero or other in utero insult.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Southwest Autism Research & Resource Center (S.A.R.R.C.) | Phoenix, Arizona, United States | — |
| University of Arizona, Pediatrics Multidisciplinary Research Unit | Tucson, Arizona, United States | — |
| Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.) | Little Rock, Arkansas, United States | — |
| N.R.C. Research Institute | Orange, California, United States | — |
| M.I.N.D. Institute (Univ.of California, Davis) | Sacramento, California, United States | — |
| University of California (U.C.S.F.) | San Francisco, California, United States | — |
| IMMUNOe Research Centers | Centennial, Colorado, United States | — |
| Yale Child Study Center | New Haven, Connecticut, United States | — |
| Segal Institute For Clinical Research | North Miami, Florida, United States | — |
| Advent Health -Lake Mary Pediatrics | Orange City, Florida, United States | — |
| A.P.G. Research | Orlando, Florida, United States | — |
| Research Institute of Deaconess Clinic | Newburgh, Indiana, United States | — |
+ 19 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.